Classement en actions
#14033
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to... Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Prix de l'action
$14.86
Dernière synchronisation: 2026-08-31
Capitalisation boursière
$442.29M
Changement (1 jour)
-1.13%
Changement (1 an)
769.01%
Échange Q32 Bio Inc. (QTTB)
Le prix QTTB avec la capitalisation boursière de B
Capitalisation boursière de Q32 Bio Inc.(QTTB)
Capitalisation boursière: $442.29M
En September 2026, Q32 Bio Inc. a une capitalisation boursière de $442.29M. Cela fait de Q32 Bio Inc. la 14033rd entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Q32 Bio Inc. du 2018 au 2026
QTTB par rapport au top 5 des plus populaires stocks
| Prix pour QTTB |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.327T
|
+1,204,260.77%
|
|
|
|
|
$4.645T
|
+1,050,080.81%
|
|
|
|
|
$4.070T
|
+920,163.32%
|
|
|
|
|
$3.785T
|
+855,572.62%
|
|
|
|
|
$2.790T
|
+630,731.31%
|
